Royal Bank of Canada Raises Stock Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Royal Bank of Canada significantly increased its stake in Cellebrite DI Ltd. by acquiring 817,244 shares, totaling 824,226 shares and representing 0.34% ownership worth approximately $16 million.
• Several other institutional investors also entered or expanded their positions in Cellebrite DI during the first quarter, contributing to 45.88% of the company's stock now being owned by hedge funds and institutional investors.
• Cellebrite DI reported earnings of $0.12 EPS, exceeding analyst expectations, with revenue of $113.28 million for the quarter, marking an 18.4% increase compared to the same quarter last year.

Royal Bank of Canada lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 11,705.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 824,226 shares of the company's stock after purchasing an additional 817,244 shares during the period. Royal Bank of Canada owned about 0.34% of Cellebrite DI worth $16,015,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CLBT. Northern Trust Corp raised its stake in Cellebrite DI by 113.6% during the 4th quarter. Northern Trust Corp now owns 211,994 shares of the company's stock worth $4,670,000 after acquiring an additional 112,731 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Cellebrite DI in the fourth quarter valued at $7,538,000. Bank of America Corp DE grew its holdings in shares of Cellebrite DI by 32.0% in the fourth quarter. Bank of America Corp DE now owns 680,375 shares of the company's stock valued at $14,989,000 after purchasing an additional 165,116 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Cellebrite DI by 3.7% in the fourth quarter. Lazard Asset Management LLC now owns 197,488 shares of the company's stock valued at $4,350,000 after purchasing an additional 7,058 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Cellebrite DI by 38.5% in the fourth quarter. Nuveen Asset Management LLC now owns 585,839 shares of the company's stock valued at $12,906,000 after purchasing an additional 162,886 shares in the last quarter. Institutional investors own 45.88% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Lake Street Capital decreased their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Finally, Wall Street Zen downgraded shares of Cellebrite DI from a "buy" rating to a "hold" rating in a report on Saturday. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $22.40.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT traded up $0.63 during midday trading on Monday, reaching $17.43. 1,790,704 shares of the company's stock were exchanged, compared to its average volume of 1,961,918. The firm's 50 day simple moving average is $15.23 and its two-hundred day simple moving average is $16.94. The stock has a market cap of $4.17 billion, a price-to-earnings ratio of -22.93, a P/E/G ratio of 3.05 and a beta of 1.28. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The firm had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company's quarterly revenue was up 18.4% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.